. Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy". Am J Hematol 2025 Apr 4. doi: 10.1002/ajh.27674.
PMID: 40183142